01

EBGLYSS Hits Endpoints in Phase 3b Hand-and-Foot Atopic Dermatitis Trial

Lilly's Phase 3b ADtouch trial shows 53% of hand-and-foot atopic dermatitis patients on EBGLYSS reached clear or almost clear skin at Week 16, versus 27% on placebo.